This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Addressing Postprandial Glucose Excursions: An Update on the Implications and New Management Strategies for Patients with Diabetes

Addressing Postprandial Glucose Excursions: An Update on the Implications and New Management Strategies for Patients with Diabetes

Format

Webcast

Time to Complete

1.75 hours

Released

August 28, 2018

Expires

August 28, 2019
Add to Queue


Live Symposium Date

May 17, 2018

Maximum Credits

1.75 / AMA PRA Category 1 CreditsTM

Accredited Provider

This activity is provided by the American Association of Clinical Endocrinologists.
Program management provided by Paradigm Medical Communications, LLC.

Commercial Supporter

This activity is supported by an educational grant from Novo Nordisk Inc.

Program Description

This webinar will discuss awareness and consequences of glycemic variability, including information gained from continuous glucose monitoring and implications in cardiovascular events. Current management strategies are assessed. New and emerging bolus agents will be presented and reviewed including the lively faculty discussion.

Table of Contents

  • Welcome and Program Overview
  • Awareness and Consequences of Glycemic Variability
  • Strategies for Managing Postprandial Glucose Excursions
  • New Approaches to Bolus Insulin Administration
  • Panel Discussion/Q&A

Intended Audience

This activity has been designed to address the educational needs of endocrinologists. It may also benefit diabetes specialists, primary care physicians, hospitalists, certified diabetes educators, PAs, nurse practitioners (NPs), pharmacists, managed care clinicians, and other clinicians who care for patients with diabetes.

Statement of Need

Despite demonstration of decreased cardiovascular risk with lowered postprandial glucose levels and the availability of fast-acting insulins to treat postprandial glucose excursions (PPGE), debate remains about the necessity of treating PPGE. It is critical that clinicians who manage patients with diabetes keep up to date with the latest emerging evidence for newer, ultra-fast-acting prandial insulins, as this is an evolving category. Whereas prandial insulin use primarily pertains to type 1 diabetes, a number of people with type 2 diabetes also benefit from prandial insulin. Endocrinologists and diabetes specialists need to understand how to tailor diabetes care according to individual patient backgrounds and characteristics, especially with respect to prandial insulin. They also require an understanding of the most recently updated guidelines about the appropriate use of prandial insulin therapy, and how patient factors influence selection of appropriate insulin regimens. This educational activity will address postprandial hyperglycemia and its treatment.

Educational Objectives

Upon proper completion of this activity, participants should be better able to:

  • Discuss the implications of postprandial hyperglycemia for patients with diabetes
  • Describe how ultra-fast-acting insulins are used to mimic physiologic insulin for patients with diabetes
  • Outline appropriate use of ultra-fast-acting insulins for patients with diabetes

Conflict Of Interest Disclosure Policy

It is the policy of AACE to ensure balance, independence, objectivity, and scientific rigor in all of its CME activities. Presentation content may include discussion of an unlabeled use of a commercial product or an investigational use of a product not yet approved for any purpose. AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature.

Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest. AACE requires speakers, faculty, CME Committee, and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation, and educational materials used as basis for content, and appropriateness of patient care recommendations.

The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence.

AACE has reviewed all disclosures and resolved or managed all identified conflicts of interest for this educational activity, as applicable.

Faculty

Richard E. Pratley, MD (Chair)
Director and Samuel E. Crockett Chair in Diabetes Research
Florida Hospital Diabetes Institute
Senior Investigator and Diabetes Program Lead
Translational Research Institute for Metabolism and Diabetes
Adjunct Professor, Sanford Burnham Prebys Medical Discovery Institute
Orlando, FL

Dr. Pratley, MD discloses the following:
Grant/Research Support: Eli Lilly and Company; Lexicon Pharmaceuticals, Inc.; Ligand Pharmaceuticals, Inc.; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceutical Company Ltd.
Retained Consultant: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Eisai, Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Ligand Pharmaceuticals, Inc.; Merck & Co., Inc; Novo Nordisk Inc.; Pfizer, Inc; sanofi-aventis U.S. LLC; Takeda Pharmaceutical Company Ltd.
Speakers Bureau: Novo Nordisk Inc; Takeda Pharmaceutical Company Ltd.

Bruce W. Bode, MD
Clinical Associate Professor
Division of Endocrinology, Metabolism and Lipids
Department of Medicine
Emory University
Atlanta, GA

Dr. Bode discloses the following:
Grant/Research Support: Abbott Laboratories; DexCom; Diasome; Mannkind Corporation; Medtronic; Novo Nordisk Inc; sanofi-aventis U.S. LLC; Senseonics
Retained Consultant: Adocia; Medtronic; Novo Nordisk Inc; sanofi-aventis U.S. LLC
Speakers Bureau: AstraZeneca; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Medtronic; Novo Nordisk Inc.; sanofi-aventis U.S. LLC.
Advisory Board: Janssen Pharmaceuticals, Inc.

Irl B. Hirsch, MD
Professor of Medicine
Diabetes Treatment and Teaching Chair
Division of Metabolism, Endocrinology and Nutrition
Department of Medicine
University of Washington
Seattle, WA

Dr. Hirsch discloses the following:
Retained Consultant: Abbott Laboratories; Intarcia Therapeutics, Inc.; Roche

Guillermo E. Umpierrez, MD
Professor of Medicine
Department of Medicine
Emory University School of Medicine
Section Chief, Diabetes and Endocrinology Division
Grady Health System
Atlanta, GA

Dr. Umpierrez discloses the following:
Grant/Research Support: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC.

CME Accreditation Committee Disclosures

Myriam Allende-Vigo, MD, MBA, FACP, FACE
Advisory Board: Merck & Co., Inc.

Joshua I. Barzilay, MD, FACE
Stockholder: AbbVie Inc; Bristol Myers Squibb Company; Merck & Co., Inc; Pfizer Inc.; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd

Tamis Bright, MD
Salary: Southwest ENT (Spouse)

Philip Raskin, MD, FACE
Advisory Board: Intarcia Therapeutics
Grant/Research Support: Amylin Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Gan & Lee Pharmaceuticals
Retained Consultant: Reata Pharmaceuticals, Inc.

Nothing to Disclose:
Ricardo Correa, MD
Diane Donegan, MBChB
Kurt Kennel, MD, FACE
Phillip D.K. Lee, MD, FAAP, FACE
Jad Sfeir, MD
Jagdeesh Ullal, MD, FACE, ECNU
Rong Mei Zhang, MD

Program Committee Disclosures

Joseph Aloi, MD, FACP
Retained Consultant: DexCom, Inc; Medtronic, Inc

Pauline M. Camacho, MD
Grant/Research Support: Amgen Inc.; NPS Pharmaceuticals
Advisory Board: Amgen Inc.

Jay Cohen, MD
Grant/Research Support: Eli Lilly and Company; Janssen Pharmaceuticals Inc; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC
Speakers Bureau: AbbVie Inc; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Corcept Therapeutics; Eli Lilly and Company; Endo Pharmaceuticals Inc; Janssen Pharmaceuticals Inc.; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC
Advisory Board: Corcept Therapeutics; Endo Pharmaceuticals Inc

Jaime A. Davidson, MD, FACP
Retained Consultant: Aspire Bariatrics; GlaxoSmithKline
Speakers Bureau: AstraZeneca/ Bristol Meyers Squibb; Janssen Pharmaceuticals Inc.; Novo Nordisk Inc.
Advisory Board: AstraZeneca/ Bristol Meyers Squibb; Eli Lilly and Company; Merck & Co., Inc; Novo Nordisk Inc.; Valeritas

Vivian Fonseca, MD (Program Vice-Chair)
Grant/Research Support: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.

Jeffrey R. Garber, MD, FACP
Retained Consultant: AbbVie Inc.; Kashiv Pharma, LLC; Titan Pharmaceuticals, Inc
Advisory Board: Lio Tri Dev

W. Timothy Garvey, MD
Grant/Research Support: AstraZeneca; Eisai Inc.; Lexicon Pharmaceuticals Inc.; Merck & Co., Inc.; Novo Nordisk Inc; Pfizer Inc.; sanofi-aventis U.S. LLC
Retained Consultant: Alexion; AstraZeneca; Eisai Inc.; Janssen Pharmaceuticals Inc; Merck & Co., Inc.; Novo Nordisk Inc; Takeda Pharmaceutical Company Ltd.
Stockholder: Bristol Myers Squibb Company; Eli Lilly and Company; ISIS; Merck & Co., Inc.; Novartis; Pfizer Inc.

Chris Guerin, MD, FACE, FNLA
Speaker’s Bureau: Abbott Medical Devices; Novo Nordisk Inc
Advisory Board: Novo Nordisk Inc.
Teaching: Janssen Pharmaceuticals Inc.; sanofi-aventis U.S. LLC

Yehuda Handelsman, MD, FACP, FNLA
Grant/Research Support: Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc; Gilead Sciences Inc.; GlaxoSmithKline; Intarcia Therapeutics; Lexicon Pharmaceuticals, Inc; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceutical Company Ltd.
Retained Consultant: Amarin Corporation; Amgen Inc.; Amylin Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Gilead Sciences Inc.; GlaxoSmithKline; Halozyme, Inc; Janssen Pharmaceuticals Inc.; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC; Vivus Inc
Speakers Bureau: Amarin Corporation; Amylin Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; GlaxoSmithKline; Janssen Pharmaceuticals Inc.; Novo Nordisk Inc.; Vivus Inc.

Shashank Joshi, MD, FACP, FRCP
Retained Consultant: Bayer Zydus Pharma; Franco Indian; Johnson & Johnson Services, Inc.; Marico; sanofi-aventis U.S. LLC
Speakers Bureau: Abbott Laboratories; AstraZeneca; Bayer Zydus Pharma; Boehringer Ingelheim Pharmaceuticals, Inc; Dr. Reddy Labs; Eli Lilly and Company; Glenmark; Johnson & Johnson Services, Inc.; Marico; MSD; Novartis; Novo Nordisk Inc.; Pfizer Inc.; Roche; sanofi-aventis US LLC; Zydus Cadilla;
Advisory Board: Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc; Novartis; Novo Nordisk Inc.; Pfizer Inc.; Roche; USV

Laurence Katznelson, MD
Grant/Research Support: Novartis; Versartis, Inc
Retained Consultant: Chiasma, Inc; Pfizer Inc.; Reset Therapeutics

Jonathan D. Leffert, MD, FACP
Grant/Research Support: AbbVie Inc; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc; Novo Nordisk Inc; sanofi-aventis U.S. LLC

Matthew J. Levine, MD, FACE
Speaker’s Bureau: AbbVie Inc.

W. Reid Litchfield, MD
Speaker’s Bureau: Novo Nordisk Inc.

Mark A. Lupo, MD, FACE, ECNU
Grant/Research Support: Eisai Inc.; Patheway Genomics; Roche Diagnostics; Rosetta Genomics; Veracyte Inc.
Speakers Bureau: AbbVie Inc.; Sanofi-Genzyme; Veracyte Inc.
Advisory Board: Rosetta Genomics; Sanofi-Genzyme

Christos Mantzoros, MD
Grant/Research Support: Eisai Inc.; Novo Nordisk Inc.
Advisory Board: Ansh; Intarcia Therapeutics Inc.; Coherus Biosciences; Novo Nordisk Inc; Pangea
Stockholder: Coherus Biosciences; Pangea

Janet B. McGill, MD
Grant/Research Support: AstraZeneca/Boehringer Ingelheim Pharmaceuticals, Inc; Novartis
Retained Consultant: Aegerion; Boehringer Ingelheim Pharmaceuticals, Inc; Dexcom, Inc.
Speakers Bureau: Aegerion; Dexcom, Inc; Janssen Pharmaceuticals Inc.; Mannkind
Advisory Board: Bayer Healthcare; Boehringer Ingelheim Pharmaceuticals, Inc; Novo Nordisk Inc.; Intarcia Therapeutics Inc.

Rachel Pessah-Pollack, MD
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc/Eli Lilly and Company; Radius Health, Inc.

Cheryl R. Rosenfeld, DO
Retained Consultant: Boehringer Ingelheim Pharmaceuticals, Inc; Eisai Inc.; Novo Nordisk Inc.
Editorial Assistance (Editor): Novartis

Susan Samson, MD, PhD, FRCPC (Program Vice Chair)
Grant/Research Support: Novartis
Advisory Board: Chiasma, Inc; Corcept Therapeutics; Novartis

Lance Sloan, MD
Speakers Bureau: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc/Eli Lilly and Company; Janssen Pharmaceuticals Inc.; Merck & Co., Inc; Orexigen Therapeutics, Inc; Salix Pharmaceuticals Inc.

Dace L. Trence, MD, FACE
Stockholder: Medtronic, Inc.; sanofi-aventis U.S. LLC.

Aaron Vinik, MD, PhD, FCP, MACP, FACE
Retained Consultant: Alnylam Pharmaceuticals, Inc.

Nelson B. Watts, MD, FACP
Lecturer: Amgen Inc.; Radius Health, Inc.; Shire
Advisory Board: Amgen Inc.
Stockholder: OsteoDynamics

Sandra L. Weber, MD, FACP
Grant/Research Support: National Institutes of Health; Novo Nordisk Inc.; sanofi-aventis U.S., LLC

Kathleen Wyne, MD, PhD, FNLA
Grant/Research Support: Eli Lilly and Company; sanofi-aventis U.S. LLC
Advisory Board: AbbVie Inc.; Novo Nordisk Inc.

Farhad Zangeneh, MD
Retained Consultant: AbbVie Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Eli Lilly and Company; Janssen Pharmaceuticals Inc.; Novo Nordisk Inc.; Pfizer Inc.
Speakers Bureau: AbbVie Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Eli Lilly and Company; Janssen Pharmaceuticals Inc.; Novo Nordisk Inc.; Pfizer Inc.

The following have nothing to disclose: Vin Tangpricha, MD, PhD; Gregory Randolph, MD; Mack Harrell, MD, FACP, FACE, ECNU; Felice Caldarella, MD, FACP, CDE; Karel Pacak, MD, PhD, DSc, FACE; David Bimston, MD; Sripriya Raman, MD; Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE; Daniel L. Hurley, MD; Harmeet S. Narula, MD, FACP; David Lieb, MD; Victor Roberts, MD, MBA, FACP; and Peter Singer, MD.

*designates a member of both faculty and program committee

Accredited Provider Disclosure

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

Credit

1.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation for this program, please contact AACE CME department at CME@aace.com.

PA Continuing Education

PAs may claim a maximum of 1.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, the American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As ACCME-accredited providers, the American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by the American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC.

Instructions

To receive a CME certificate of participation, participants must:
  • Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pre-activity assessment.
  • View the online activity in its entirety.
  • Complete and submit the online post-activity assessment and evaluation.
A certificate of participation will be available for download/printing immediately following your successful completion of the post-activity assessment and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your myCME CME History.

For information about the accreditation for this program, please contact AACE CME department at CME@aace.com.

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

There is no fee required for participation in this activity.

Technical Requirements

This certified CME activity is designed using HTML5 video. As you navigate using the supplied controls, the slides will sync to the speaker.

For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Terms of Use and Privacy Policy

Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of the American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by the American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC. The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, accept no liability for the content referenced in this activity.

Privacy Policy
The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, are committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by the American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, to continuously improve the learning experience.

The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, do not transfer, sell, or share personal information with outside parties. The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.

LEARNER BILL OF RIGHTS
The American Association of Clinical Endocrinologists (AACE) recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill, or performance. As part of AACE’s duty to you as a learner, you have the right to expect that your continuing medical education experience with AACE includes:


CONTENT that:

  • Promotes improvements or quality in healthcare
  • Is valid, reliable, and accurate
  • Offers balanced presentations that are free of commercial bias for or against a product/service
  • Is vetted through a process that resolves any conflicts of interest of planners, teachers, or authors
  • Is driven and based on learning needs, not commercial interests
  • Addresses the stated objectives or purpose
  • Is evaluated for its effectiveness in meeting the identified educational need

A LEARNING ENVIRONMENT that:

  • Supports learners’ ability to meet their individual needs
  • Respects and attends to any special needs of the learners
  • Respects the diversity of groups of learners
  • Is free of promotional, commercial, and/or sales activities

DISCLOSURE of:

  • Relevant financial relationships planners, teachers and authors have with commercial interests related to the content of the activity
  • Commercial support (funding or in-kind resources) of the activity.

myCME privacy policy

Copyright

Copyright 2018, AACE. All rights reserved. No part of this enduring material may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission from AACE.
Add to Queue